WALTHAM, Mass. — May 31, 2017 — Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, today announced that CEO, Manos Perros will present at two upcoming investor conferences in June, the Jefferies Global Healthcare Conference taking place in New York, NY on June 6 to 9, and the JMP Securities Life Sciences Conference on June 20 to 21, also taking place in New York City.

Details of the presentations are as follows:

Jefferies Global Healthcare Conference
Date: Tuesday, June 6, 2017
Time: 2pm ET
Forum: Corporate Presentation
Location: New York

JMP Securities Life Sciences Conference
Date: Wednesday, June 21, 2017
Time: 12:30pm ET
Forum: Panel Discussion on Antibiotics
Location: New York

About Entasis Therapeutics Inc.

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumanniiinfections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae). www.entasistx.com

Company Contact
Kyle Dow
Entasis Therapeutics
(781) 810-0114
kyle.dow@entasistx.com

Media Contact
Kari Watson
MacDougall Biomedical Communications (781) 235-3060
kwatson@macbiocom.com